Mitochondrial Reprogramming in Peripheral Blood Mononuclear Cells of Patients with Glycogen Storage Disease Type Ia

Overview

Journal Genes Nutr

Publisher Biomed Central

Date 2023 Jun 6

PMID 37280548

Authors

Alessandro Rossi

Antonia Assunto

Carmen Rosano

Sara Tucci

Margherita Ruoppolo

Marianna Caterino

Francesca Pirozzi

Pietro Strisciuglio

Giancarlo Parenti

Daniela Melis

Affiliations

Soon will be listed here.

Abstract

Background: Glycogen storage disease type Ia (GSDIa) is an inborn metabolic disorder caused by the deficiency of glucose-6-phospatase-α (G6Pase-α) leading to mitochondrial dysfunction. It remains unclear whether mitochondrial dysfunction is present in patients' peripheral blood mononuclear cells (PBMC) and whether dietary treatment can play a role. The aim of this study was to investigate mitochondrial function in PBMC of GSDIa patients.

Methods: Ten GSDIa patients and 10 age-, sex- and fasting-time matched controls were enrolled. Expression of genes involved in mitochondrial function and activity of key fatty acid oxidation (FAO) and Krebs cycle proteins were assessed in PBMC. Targeted metabolomics and assessment of metabolic control markers were also performed.

Results: Adult GSDIa patients showed increased CPT1A, SDHB, TFAM, mTOR expression (p < 0.05) and increased VLCAD, CPT2 and citrate synthase activity in PBMC (p < 0.05). VLCAD activity directly correlated with WC (p < 0.01), BMI (p < 0.05), serum malonycarnitine levels (p < 0.05). CPT2 activity directly correlated with BMI (p < 0.05).

Conclusion: Mitochondrial reprogramming is detectable in PBMC of GSDIa patients. This feature may develop as an adaptation to the liver enzyme defect and may be triggered by dietary (over)treatment in the frame of G6Pase-α deficiency. PBMC can represent an adequate mean to assess (diet-induced) metabolic disturbances in GSDIa.

Citing Articles

Shaker/Kv1 potassium channel SHK-1 protects against pathogen infection and oxidative stress in C. elegans.

Pu L, Wang J, Nilsson L, Zhao L, Williams C, Chi G PLoS Genet. 2025; 21(2):e1011554.

PMID: 39913540 PMC: 11849984. DOI: 10.1371/journal.pgen.1011554.

A machine learning model accurately identifies glycogen storage disease Ia patients based on plasma acylcarnitine profiles.

Groen J, de Haan B, Overduin R, Haijer-Schreuder A, Derks T, Heiner-Fokkema M Orphanet J Rare Dis. 2025; 20(1):15.

PMID: 39789579 PMC: 11721056. DOI: 10.1186/s13023-025-03537-2.

Mitochondrial Dysfunction in Glycogen Storage Disorders (GSDs).

Mishra K, Kakhlon O Biomolecules. 2024; 14(9).

PMID: 39334863 PMC: 11430448. DOI: 10.3390/biom14091096.

Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care.

Rossi A, Simeoli C, Pivonello R, Salerno M, Rosano C, Brunetti B Rev Endocr Metab Disord. 2024; 25(4):707-725.

PMID: 38556561 PMC: 11294274. DOI: 10.1007/s11154-024-09880-2.

From common to rare: repurposing of bempedoic acid for the treatment of glycogen storage disease type 1.

Das A Genes Nutr. 2023; 18(1):15.

PMID: 37723434 PMC: 10508021. DOI: 10.1186/s12263-023-00733-2.

References

Riede U, Spycher M, GITZELMANN R . Glycogenosis type I (glucose 6-phosphatase deficiency): I. Ultrastructural morphometric analysis of juvenile liver cells. Pathol Res Pract. 1980; 167(1):136-50. DOI: 10.1016/S0344-0338(80)80185-3. View

Mihalik S, Goodpaster B, Kelley D, Chace D, Vockley J, Toledo F . Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010; 18(9):1695-700. PMC: 3984458. DOI: 10.1038/oby.2009.510. View

Diaz-Rua R, Palou A, Oliver P . gene expression in peripheral blood mononuclear cells as an early biomarker of diet-related metabolic alterations. Food Nutr Res. 2016; 60:33554. PMC: 5123217. DOI: 10.3402/fnr.v60.33554. View

Cangelosi D, Resaz R, Petretto A, Segalerba D, Ognibene M, Raggi F . A Proteomic Analysis of GSD-1a in Mouse Livers: Evidence for Metabolic Reprogramming, Inflammation, and Macrophage Polarization. J Proteome Res. 2019; 18(7):2965-2978. DOI: 10.1021/acs.jproteome.9b00309. View

Das A, Lucke T, Meyer U, Hartmann H, Illsinger S . Glycogen storage disease type 1: impact of medium-chain triglycerides on metabolic control and growth. Ann Nutr Metab. 2010; 56(3):225-32. DOI: 10.1159/000283242. View

de Mello V, Kolehmanien M, Schwab U, Pulkkinen L, Uusitupa M . Gene expression of peripheral blood mononuclear cells as a tool in dietary intervention studies: What do we know so far?. Mol Nutr Food Res. 2012; 56(7):1160-72. DOI: 10.1002/mnfr.201100685. View

Jung U, Seo Y, Ryu R, Choi M . Differences in metabolic biomarkers in the blood and gene expression profiles of peripheral blood mononuclear cells among normal weight, mildly obese and moderately obese subjects. Br J Nutr. 2016; 116(6):1022-32. DOI: 10.1017/S0007114516002993. View

Vernochet C, Mourier A, Bezy O, Macotela Y, Boucher J, Rardin M . Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance. Cell Metab. 2012; 16(6):765-76. PMC: 3529641. DOI: 10.1016/j.cmet.2012.10.016. View

Rutten M, Derks T, Huijkman N, Bos T, Kloosterhuis N, van de Kolk K . Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing. Hepatology. 2021; 74(5):2491-2507. PMC: 8597008. DOI: 10.1002/hep.32022. View

10.

Hannibal L, Theimer J, Wingert V, Klotz K, Bierschenk I, Nitschke R . Metabolic Profiling in Human Fibroblasts Enables Subtype Clustering in Glycogen Storage Disease. Front Endocrinol (Lausanne). 2020; 11:579981. PMC: 7719825. DOI: 10.3389/fendo.2020.579981. View

11.

Yavarow Z, Kang H, Waskowicz L, Bay B, Young S, Yen P . Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia. Hum Mol Genet. 2019; 29(2):286-294. PMC: 7003036. DOI: 10.1093/hmg/ddz290. View

12.

Villani G, Gallo G, Scolamiero E, Salvatore F, Ruoppolo M . "Classical organic acidurias": diagnosis and pathogenesis. Clin Exp Med. 2016; 17(3):305-323. DOI: 10.1007/s10238-016-0435-0. View

13.

Melis D, Rossi A, Pivonello R, Salerno M, Balivo F, Spadarella S . Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. Orphanet J Rare Dis. 2015; 10:91. PMC: 4518509. DOI: 10.1186/s13023-015-0301-2. View

14.

Wang J, Chen Y, Song Q, Griffiths A, Song Z . mTORC1-IRE1α pathway activation contributes to palmitate-elicited triglyceride secretion and cell death in hepatocytes. Exp Biol Med (Maywood). 2020; 245(14):1268-1279. PMC: 7437378. DOI: 10.1177/1535370220928276. View

15.

Ricoult S, Manning B . The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep. 2013; 14(3):242-51. PMC: 3589096. DOI: 10.1038/embor.2013.5. View

16.

Scolamiero E, Cozzolino C, Albano L, Ansalone A, Caterino M, Corbo G . Targeted metabolomics in the expanded newborn screening for inborn errors of metabolism. Mol Biosyst. 2015; 11(6):1525-35. DOI: 10.1039/c4mb00729h. View

17.

Houten S, Violante S, Ventura F, Wanders R . The Biochemistry and Physiology of Mitochondrial Fatty Acid β-Oxidation and Its Genetic Disorders. Annu Rev Physiol. 2015; 78:23-44. DOI: 10.1146/annurev-physiol-021115-105045. View

18.

Mao Z, Zhang W . Role of mTOR in Glucose and Lipid Metabolism. Int J Mol Sci. 2018; 19(7). PMC: 6073766. DOI: 10.3390/ijms19072043. View

19.

Kurbatova O, Izmailova T, Surkov A, Namazova-Baranova L, Poliakova S, Miroshkina L . [Mitochondrial dysfunction in children with hepatic forms of glycogen storage disease]. Vestn Ross Akad Med Nauk. 2015; (7-8):78-84. DOI: 10.15690/vramn.v69i7-8.1112. View

20.

Derks T, Rodriguez-Buritica D, Ahmad A, de Boer F, Couce M, Grunert S . Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs. Nutrients. 2021; 13(11). PMC: 8621617. DOI: 10.3390/nu13113828. View